Novartis Ag (NVS) Short-term Investments (2009 - 2026)

Novartis Ag has reported Short-term Investments for 18 years, with the latest figure at $74.0 million in Q2 2026.

• Quarterly Short-term Investments fell 78.49% year-over-year to $74.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $74.0 million (down 78.49% YoY) and the FY2025 annual result came in at $155.0 million, up 153.63% from the prior year.
• Short-term Investments fell to $74.0 million in Q2 2026 per NVS's latest filing, from $100.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $11.4 billion in Q4 2022 and troughed at -$17.5 billion in Q2 2022.
• A 5-year average of -$214.1 million and a median of $197.0 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments slumped 7402.93% in 2022, then surged 5700.0% in 2023.
• Over 5 years, Short-term Investments stood at $11.4 billion in 2022, then slumped by 105.62% to -$641.0 million in 2023, then surged by 104.84% to $31.0 million in 2024, then soared by 400.0% to $155.0 million in 2025, then sank by 52.26% to $74.0 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $74.0 million, $100.0 million, and $155.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.